Answers are grounded in this paper and cite their sources.
Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of health care-associated infections. Vancomycin remains an acceptable treatment option. There has been a welcome increase in the number of agents available for the treatment of MRSA infection. These drugs have certain differentiating attributes and may offer some advantages over vancomycin, but they also have significant limitations. These agents provide some alternative when no other options are available.
No takes yet. Share an insight, caveat, or question.
Choo et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: